EHA 2020 | Personalized medicine for DLBCL

Ulrich Jäger, MD, of Medical University of Vienna, Vienna, Austria, discusses applications of personalized therapy in diffuse large B-cell lymphoma (DLBCL) and highlights the importance of ongoing clinical trials investigating this approach. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).